COMMUNIQUÉS West-GlobeNewswire

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
20/05/2026
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in patients with [...]
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
20/05/2026
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry TORONTO, May 20, 2026 (GLOBE NEWSWIRE [...]
Medline Inc. announces launch of secondary offering of Class A common stock
20/05/2026
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned [...]
Lung Health Foundation Says Canada’s Current Access System to Emerging Therapies is Moving Slower than Modern Medicine
20/05/2026
New lung cancer and respiratory treatments are being developed faster than critically ill Canadian patients can access them, even when doctors believe they could help save lives; Canada’s largest charity dedicated to [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
23andMe Partners with HealthEx to Connect Medical Records with Your DNA for the Future of Personalized Medicine
20/05/2026
23andMe’s new AI Health Summary Turns Genetics, Medical Records, Labs, and Lifestyle Data Into Personalized, Evidence-Based Recommendations PALO ALTO, Calif. and SAN FRANCISCO, May 20, 2026 (GLOBE NEWSWIRE) -- 23andMe [...]
Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform
20/05/2026
ANN ARBOR, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced additional [...]
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
20/05/2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary [...]
Vistin Pharma ASA: Minutes from the annual general meeting 2026
20/05/2026
Oslo, Norway, 20 May 2026 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 20 May 2026. Attachment Minutes from AGM Vistin Pharma ASA_20_May_2026
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
20/05/2026
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells IGI’s clinically validated BEAT ® platform enabled the development of [...]
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases [...]
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent
20/05/2026
BioStem Technologies Expands Global Placental Allograft Patent Portfolio Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and [...]
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
20/05/2026
Multi-year partnership lands as Prenetics’ IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8’s first global ambassador from [...]
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
20/05/2026
REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA [...]
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
20/05/2026
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the [...]
Tru-1 By BlueGenes Launches to Advance Precision Health Through Smarter Genetic Insights
20/05/2026
New platform aims to help healthcare organizations and patients make more informed medication and wellness decisions through data-driven genetic testing SCOTTSDALE, Ariz., May 20, 2026 (GLOBE NEWSWIRE) -- Tru-1 by [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20/05/2026
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically “cold” tumors [...]
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
20/05/2026
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE [...]

Pages